@article{Bogner_Ferrero_Marin_Bataille_2021, title={Peritoneal dialysis catheter dysfunction due to fibrin clots following treatment with tranexamic acid: a clinical case}, volume={4}, url={https://www.bdd.rdplf.org/index.php/bdd/article/view/61393}, DOI={10.25796/bdd.v4i2.61393}, abstractNote={<p>Chronic kidney disease patients experience not only more frequent arterial and venous thrombosis but also hemorrhagic episodes. Tranexamic acid is an anti-fibrinolytic molecule that inhibits plasmin activation. It is used in hemorrhage cases (post-traumatic, gynecologic, or gastrointestinal bleeding).</p> <p>We report on an original case of tranexamic acid (Exacyl®) use in a peritoneal dialysis patient for gastrointestinal bleeding of unknown origin. The use of tranexamic acid led to the Tenckhoff catheter dysfunction because of fibrin clots in the dialysate.</p> <p>The emergence of fibrin clots a few days after the start of tranexamic acid treatment, which never occurred again after the end of the treatment, and the anti-fibrinolytic function of tranexamic acid favors this treatment’s role in fibrin clot occurrence.</p>}, number={2}, journal={Bulletin de la Dialyse à Domicile}, author={Bogner, Elodie and Ferrero, Elodie and Marin, Joelle and Bataille, Stanislas}, year={2021}, month={May}, pages={121–128} }